Marina Biotech Announces Resignation of Chairman, President

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Marina Biotech Announces Resignation of Chairman, President and Chief Executive Officer J. Michael French

BOTHELL, WA--(Marketwired - Jun 2, 2016) - Marina Biotech, Inc. ( OTCQB : MRNA ), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announcd that J. Michael French, chairman of the board, president and chief executive officer, is resigning effective June 10, 2016 to pursue other opportunities. Current board member, Joseph W. Ramelli, will assume the roles of chairman of the board and acting chief executive officer. The board of directors is currently conducting a search for a new CEO.

"The Board thanks Mr. French for his efforts and leadership of Marina, including the transition of the company from an oligonucleotide therapeutics company to a late-stage therapeutics company, with the pending completion of our proposed agreement with Turing Pharmaceuticals for its late-stage intranasal ketamine program. We wish him well in his future endeavors," said Mr. Ramelli. "The Board has already begun a search for a new Chief Executive Officer with the expertise and experience necessary to fully execute on the opportunity provided by the ketamine program."

About Marina Biotech, Inc. Marina Biotech is an oligonucleotide therapeutics company with broad drug discovery technologies providing the ability to develop proprietary single and double-stranded nucleic acid therapeutics including siRNAs, microRNA mimics, antagomirs, and antisense compounds, including messengerRNA therapeutics. These technologies were built via a roll-up strategy to discover and develop different types of nucleic acid therapeutics in order to modulate (up or down) a specific protein(s) which is either being produced too much or too little thereby causing a particular disease. We believe that the Marina Biotech technologies have unique strengths as a drug discovery engine for the development of nucleic acid-based therapeutics for rare and orphan diseases. Further, we believe Marina Biotech is the only company in the sector that has a delivery technology in human clinical trials with differentiated classes of payloads, through licensees ProNAi Therapeutics and Mirna Therapeutics, delivering single-stranded and double-stranded nucleic acid payloads, respectively. In addition to these companies, we have also licensed the delivery technology to an undisclosed company developing a gene editing approach to the treatment of human diseases. Our novel chemistries and other delivery technologies have been validated through license agreements with Roche, Novartis, Monsanto, and Tekmira. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and a preclinical program in myotonic dystrophy. Marina Biotech's goal is to improve human health through the development of RNAi- and oligonucleotide-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at www.marinabio.com .

Recently, Marina announced an agreement with Turing Pharmaceuticals AG under which Marina intends to acquire Turing's intranasal ketamine program. The program has been advanced worldwide with plans for U.S. and international clinical trial sites. The work thus far has predominately been directed at suicidality in post-traumatic stress disorder; a patient population with few, if any, therapeutic options. We believe the early clinical successes of this program combined with broadening acceptance of ketamine as a treatment for neurological and psychiatric diseases, presents a unique opportunity to rapidly move this compound into the U.S. market as early as 2019. In addition, there is some earlier work by academic centers suggesting that intranasal ketamine might be efficacious in patients suffering from certain rare diseases. In addition, the Company will also continue to seek alternatives for its nucleic acid therapeutics assets in order to maximize shareholder value. These alternatives could include the licensing and/or sale of individual nucleic acid chemistry and delivery technologies as well as the sale of the entire drug discovery platform.

Marina Biotech Forward-Looking Statements Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Marina Biotech to consummate the proposed asset acquisition transaction with Turing; (ii) the ability of Marina Biotech to obtain immediate additional funding; (iii) the ability of Marina Biotech to attract and/or maintain manufacturing, research, development and commercialization partners; (iv) the ability of Marina Biotech and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (v) the ability of Marina Biotech and/or a partner to obtain required governmental approvals; and (vi) the ability of Marina Biotech and/or a partner to develop and commercialize products prior to, and that can compete favorably with those of, competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Marina Biotech's most recent filings with the Securities and Exchange Commission. Marina Biotech assumes no obligation to update or supplement forward-looking statements because of subsequent events.

For Marina inquires: Joesph Ramelli Chairman, Acting CEO Marina Biotech, Inc. (805) 262 7621

Scroll down for more posts ▼

Top 10 Most Recent News Articles

RBC Grabs Top Honors for Sustainable Investing Leadership

Updated Category News Views 70

A New Feather in RBC's Cap RBC Wealth Management has racked up more accolades, crowned as the Best Private Bank in Canada and celebrated for its prowess in impact and sustainable investing on the global stage. These distinctions flew in courtesy of the PWM Global Private Banking Awards—a heavyweight recognition in the wealth management world. Award Winning Strategy in...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 279

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Parallels Desktop Tops 2026 Picks for Windows on Mac

Updated Category News Views 59

Diving into the Cross-Platform Conundrum Now, I've been in the trenches long enough to know that when companies start relying on Mac computers but can't ditch their essential Windows apps, they're bound to hit a digital brick wall. Picture this—accounting, enterprise management, all that jazz that still needs Windows to function. For those jumping between these two...

Continue Reading
Net Zero Efforts to Cost Europe €60B Annually by 2050

Updated Category News Views 100

Hefty Prices Loom Over Net Zero Commitments Well, strap in for a wallet buster, folks. Europe's largest players are staring down the barrel of a colossal €60 billion annual bill to clean up their carbon mess by 2050. That's the ticker in Senken's latest report, 'Pace of Change 2026.' Talks like these remind me there's no such thing as a free lunch, especially when...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 115

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Trades Workforce Shortage Costs Wallop U.S. Economy

Updated Category News Views 36

The Forgotten Backbone of America Don't sleep on this: America's got itself a trade worker crisis, and it's not just a numerical hiccup. We’re down nearly 1.9 million skilled trades workers, and that's a gut punch to the economy—a hefty $1.2 billion a day in GDP loss. These are the folks who keep the wheels greased, the lights on, and the goods flowing. Without them,...

Continue Reading
Gayatri Pariwar Celebrates 100 Years with Massive Yoga Event

Updated Category News Views 72

An Impressive Centenary for Gayatri Pariwar Sometimes, you get hit by a wave so big you can't ignore it, and Gayatri Pariwar's centennial festival in New Delhi was one such tsunami. Picture this: countless souls gathered to mark a hundred years of spiritual and social reform, not just with chants and talks, but through an awe-inspiring mass yoga event. In my decades...

Continue Reading
Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 62

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading
Dar Global Expands Jeddah Portfolio with $267M Project

Updated Category News Views 120

Dar Global's Big Jeddah Move: A $267M Bet Alright, let's dive into what Dar Global's been up to in Saudi Arabia. They've just announced a whopping SAR 1 billion development project in Jeddah, bringing an international luxury brand to the city with an exclusive co-branded residential concept. Now that's something to chew on for any investor eyeing the Middle East's real...

Continue Reading
Ozelle Unveils AI-Powered Hematology Tool at MEDICA 2026

Updated Category News Views 116

Pioneering a New Era in Hematology In the fast-paced world of blood analysis, standing still means being left in the dust. Ozelle, with its AI-powered innovative tool, is making waves at MEDICA 2026 in Düsseldorf. Meet O-Cyte 1, an automated hematology analyzer that's merging high-resolution cell imaging with routine CBC (Complete Blood Count) testing. Sounds like...

Continue Reading

Top 5 Most Recently Viewed Articles

Westhaven Gold Secures $3.16 Million Investment for Growth

Updated Category News Views 128

Westhaven Gold Corp. Completes Strategic Private Placement Westhaven Gold Corp. (TSXV: WHN) has successfully closed a non-brokered private placement, raising a substantial $3.16 million to fuel its growth initiatives. This offering comprised the sale of units at a pivotal time for the company, allowing it to enhance its exploration and development capabilities. Details of...

Continue Reading
Revolutionizing Social Media: Alexis Ohanian and Kevin Rose Join Forces

Updated Category News Views 290

Reviving a Social Media Pioneer: Ohanian and Rose Unite In a surprising turn of events, social media titans Kevin Rose and Alexis Ohanian have teamed up to acquire the pioneering social platform, Digg. Both are recognized as early influencers in the tech industry, having co-founded some of the most notable platforms of the early web era. Now, their mission is clear: to...

Continue Reading
Exploring Innovation in CBA's Tech Ecosystem for 2024

Updated Category News Views 1337

Unveiling the Commonwealth Bank of Australia's Tech Innovations In the ever-evolving landscape of finance and technology, Commonwealth Bank of Australia (CBA) stands out as a leader. Their commitment to embracing digital transformation is not just a business strategy; it’s a comprehensive initiative that is reshaping how banking and financial services operate. The...

Continue Reading
Sheralven and Game On Team Up for Messi's Signature Fragrance

Updated Category News Views 167

Sheralven and Game On Join Forces for Messi Fragrance Launch In an exciting partnership that combines sports and beauty, Sheralven, a leader in the beauty industry, has teamed up with Game On Product Group to exclusively distribute the much-anticipated Messi Eau de Parfum in North America. This marks a significant collaboration as the fragrance is the first signature...

Continue Reading
CK Health Plus Secures Direct Selling License in Malaysia

Updated Category News Views 176

CK Health Plus Achieves Milestone in Malaysia CK Health Plus Sdn. Bhd., a subsidiary of EUDA Health Holdings Limited (NASDAQ: EUDA), has recently achieved a significant milestone by securing a Direct Selling License in Malaysia. This achievement reinforces the Company’s commitment to expanding its non-invasive healthcare offerings across Asia. Understanding the...

Continue Reading